Objectives: Bone marrow derived endothelial progenitor cells (BM-EPCs) are increased in chronic liver disease (CLD). Their role in hepatic fibrosis and regeneration remains an area of intense studies. We investigated the migration and secretory functions of BM-EPCs in fibrotic mice liver.
increased endogenous levels of circulating EPCs in patients with cirrhosis as compared to the controls, suggesting enhanced mobilization of these cells in CLD patients. Our study has also revealed that these circulating EPCs interact with resident LSECs via paracine mediators including VEGF and PDGF-BB and enhance their angiogenic functions in vitro. 12 In the current study, we investigated the numbers of endogenous EPCs in BM, blood and the liver during progressive liver injury using green florescent protein (GFP)-bone marrow transplanted cells in CCL 4 -induced liver injury mouse models for up to 8 weeks. Further, we studied the correlation of EPC numbers in the liver with liver fibrosis at different weeks in these mouse models. Moreover, interactions of EPCs with HSCs were also analyzed in the in vitro cultures to determine the role of EPCs in liver fibrosis.
| MATERIALS AND METHODS

| Development of the fibrotic mouse model
All experiments were conducted as approved by the Institutional Animal Ethics Committee of NII, New Delhi. Another batch of C57BL6 mice were lethally irradiated (900 cGy) and 10 × 10 6 GFP bone marrow cells were transplanted through intrafemoral route. After 21 days, percentage of chimerism was checked in peripheral blood by flow cytometry. Mice with more than 80% chimerism were selected and given intra-peritoneal 0.4 ml CCl 4 /kg b.w.
in olive oil, twice a week, for 8 weeks. Mice were sacrificed after 48 h of each CCl 4 injection for peripheral blood and bone marrow analysis ( Figure 1B ). Transplanted C57BL6J mice, without any CCl 4 dosage were used as controls.
| Analysis of EPCs in bone marrow
At each time point, bone marrow and peripheral blood mononuclear cells were separated. 6 x 10 6 cells were stained with 5 μg/ml Hoechst and 1 μg/ml pyronin separately for 1 h at 37°C for cell cycle analysis.
The cells were stained with the anti-CD34 and Flk-1for EPCs and analyzed by BDFACSAria III (BD Biosciences) using DIVA software.
| Analysis of EPCs in peripheral blood
At each time point, peripheral blood was collected by puncturing the retro-orbital sinus. After plasma removal and RBC lysis, the cells were incubated with the anti-CD34 (biotinylated rat antimouse, e-Biosciences; 1:100) and Flk-1 (APC conjugated rat antimouse, BD; 1:50) in PBS for 30 min at 4°C, followed by incubation with secondary antibody for CD34 (streptavidin anti-rat APC-Cy7, BD; 1:400) for 30 min at 4°C. The cells were then fixed with 4%
PFA in PBS and analyzed by BDFACSAria III (BD Biosciences) using DIVA software.
| Analysis of EPCs in liver
Liver perfusion was done at 2nd, 4th, 6th and 8th week of CCl 4 dosage to isolate single cell suspension of non-parenchymal cells. The liver was perfused through the heart using HBSS-EGTA-HEPES buffer and then digested with 0.025% collagenase in HBSS-HEPES buffer. The liver was shaken off in 15% RPMI using forceps to release the cells. The cell suspension was passed through 100 μm filter and hepatocytes were removed by cen- 
| Histopathology and immunofluorescence
At each time point, liver was isolated from the same mouse whose peripheral blood was collected. Half of the tissue was fixed in 10%
formalin for embedding in paraffin and the other half was fixed in 4%
PFA for cryoembedding in OCT. H&E and picrosirius staining were Nuclear staining was done using DAPI (1:1000, Sigma) and analyzed on Olympus fluorescence microscope.
| Quantification of degree of fibrosis
The percentage of collagen proportionate area was calculated in 20X images of picrosirius stained liver sections using Image J software (NIH, Bethesda, USA).
| In-vitro culture of EPCs
Mononuclear cells (MNCs) from the bone marrow of a normal 
| In-vitro culture of HSCs
Liver non-parenchymal cells (NPC) from a normal C57BL6J mouse were isolated by perfusion as before. Hepatic stellate cells (HSCs)
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from the NPC fraction were separated by density gradient centrifugation using 27% histodenz (Sigma). Separated HSCs were collected and cultured in 10% DMEM F-12 medium for 5 days.
| EPC-HSC interactions
For the in vitro assay, the HSCs were trypsinized and replated on sterile coverslips in a 24-well plate, with 10,000 cells in each well. The cells were allowed to grow in 10% DMEM F-12 medium for 3 days and on the third day, medium was replaced with the EPC conditioned medium, or with serum free endothelial basal media (EBM-2, Lonza, Basel, Switzerland) as control. The culture medium was collected from each well after 24 h for VEGF and TGF-β ELISA assays. (anti-mouse, Invitrogen, MA, USA; 1:200) was done for 2 h at room temperature. Nuclear staining was done using DAPI (1:1000, Sigma).
Washing was done using 0.1% triton X-100 in PBS. The coverslips were removed from each well, mounted and stained cells were photographed on fluorescence microscope.
| Statistical analysis
Results of multiple experiments were reported as mean ± SD (Standard Deviation). Graph pad Prism software, Version 5.02 was used for ANOVA statistical analysis. P < 0.05 were considered significant (* < 0.05; ** < 0.01; *** < 0.005).
| RESULTS
| Establishment of chronic liver injury model
CCl 4 based fibrotic mouse model was made as described earlier. Figure 1D ). Finally, persistent liver injury was marked by the elevated levels of ALT and AST ( Figure 1E ).
| Enumeration of EPCs in bone marrow (BM) and peripheral blood (PB)
The presence of donor-derived EPCs in BM and PB was determined by In comparison with the controls without CCl4 treatment, there was an increase in the EPC proliferation in the BM right after the administration of CCl 4 . However, statistically significant increases in the EPC proliferation in the BM were observed only at the 6th week CCl 4 treatment (P < 0.01, Figure 2B ). However, we did not find any significant difference in the EPC numbers in the BM, despite of the activation of cell cycle ( Figure 2C ). This may be attributed to the egress of
EPCs from the BM to the PB.
In the PB, the number of EPCs was significantly higher at 2 weeks of CCl 4 administration compared to the controls, (P < 0.01, Figure 2C ).
Interestingly, their levels drastically declined during the 4th week. After that, it further increased in the subsequent weeks ( Figure 2C ). These results suggest that the levels of BM-derived EPCs in the PB do not remain at a steady value and that they are governed by the number of cells egressing from the BM and the number of cells going to the liver.
| Enumeration of EPC in liver
After CCL4 injury, we anticipated that these mobilized BM-derived EPCs, at least in part, will home and engraft in the liver. 
| Study of EPC-HSC interactions in-vitro
To elucidate the interactions between EPCs and HSCs, in vitro cultures of HSCs with or without EPCs conditioned medium were performed.
After 24 h, VEGF and TGF-β were quantified in the culture medium.
VEGF and TGF-β were significantly increased in HSCs within 24 h of co-cultures with the EPC conditioned medium ( Figure 4A ). The treated HSCs also showed an increased expression of α-SMA, indicating their activation (Figure 4,C) . In immunohistochemical analysis, other markers of fibrosis was also included as increased collagen 1 in the bridging necrosis at 2nd week and at 4th week, but Timp 1 expression was found more in 2nd week than in 4th week (Supplementary Figure 2C,D) .
| DISCUSSION
Bone marrow chimeric mice have been extensively used to investigate the mechanisms of tissue regeneration, cell migration and disease pathogenesis. [14] [15] [16] In this study, we generated GFP chimeric mice to track the migration of EPCs from bone marrow to the peripheral blood and finally their engraftment in the damaged liver.
The study suggested that cell cycle activation of EPCs in the bone marrow and liver injury are closely related. Bone marrow responds to liver injury through a potential autocrine loop, resulting in activation and proliferation of EPCs. The autocrine factor(s) responsible for such physiological changes, however, remain to be identified. Probably, these factors(s) are mitogenic and are secreted in the damaged liver for self-regeneration. Despite cell cycle activation, we did not observe any significant changes in EPC numbers in the bone marrow with time.
This could be due to the dynamic nature of the cells, which proliferate and at the same time egress from the bone marrow, resulting in maintenance of cell number.
In the blood, we observed an increase in circulating EPCs during early stage of the liver injury, which however declined to a lowest value in 4th week. This decline is attributed to the engraftment of cells to the and portal vein route. 17 It is, however, to be noted that with increasing CCl 4 mediated injury, there was a sharp decrease in the number of EPCs in the liver at 6th week. There was a substantial positive correlation of EPC numbers with liver fibrosis till 4th week of CCl 4 treatment, indicating a potential role of EPCs in liver fibrosis. In our earlier study, we had reported that higher EPC numbers in patients with cirrhosis
correlates significantly with the degree of fibrosis in these patients.
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It has been documented that EPCs contribute to postnatal neovasculogenesis by converting into matured form and integrating into growing vessels in cirrhotics and HCC patients. 18 In the present study, the immunofluorescence images, **P value is >.005, ***P value is >.0001
